Cefiderocol is a newer IV antibiotic with a unique mechanism and spectrum.
- What it is: Cefiderocol (brand name Fetroja) is a siderophore cephalosporin. It’s given by IV infusion and is designed to treat difficult Gram-negative infections, especially those caused by multidrug-resistant organisms.
- How it works: It uses a "Trojan horse" approach. The drug chelates iron and uses the bacterial iron uptake system to enter cells, where the beta-lactam core inhibits cell wall synthesis. This helps it stay active against many beta-lactamase-producing organisms.
- Spectrum and activity:
- Broad activity against many Gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacterales, including carbapenem-resistant strains.
- Generally not active against Gram-positive organisms (no MRSA) or anaerobes.
- Activity is retained against many beta-lactamase producers, but there can be resistance mechanisms (e.g., changes in iron transport) that reduce effectiveness.
- Indications (as of labeling):
- Adults with complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Gram-negative bacteria.
- Adults with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated pneumonia (VABP) in some indications.
- Use is typically prioritized when there are limited options due to MDR organisms.
- Dosing and administration:
- Common regimen is 2 g IV every 8 hours, infused over about 3 hours.
- Renal impairment requires dose adjustments (dosage and frequency depend on creatinine clearance); hepatic impairment does not usually require dose changes.
- Durations are typically 7 days for cUTI and may be longer for HABP/VABP, depending on organism and clinical response.
- Always refer to the official prescribing information for exact dosing tables and adjustments.
- Safety and warnings:
- Boxed warning related to higher all-cause mortality observed in infections caused by carbapenem-resistant organisms in some comparative studies; use with caution in those scenarios and consider alternative therapies when appropriate.
- Common adverse effects: nausea, diarrhea, constipation, vomiting, rash, infusion-site reactions.
- Risks of Clostridioides difficile infection, allergic reactions, and hypersensitivity.
- Probenecid can increase cefiderocol levels; consider drug interactions with nephrotoxic agents.
- Resistance considerations:
- Resistance can emerge via alterations in iron transport mechanisms of bacteria or other changes reducing drug entry.
- Not a universal solution for all MDR Gram-negatives; susceptibility testing is important.
- Special considerations:
- Not typically a first-line agent; reserved for infections caused by Gram-negative MDR pathogens where other options are limited.
- Pregnancy category B (data limited); use only if clearly needed and after weighing risks and benefits.
- Not a standard agent for Gram-positive pathogens or anaerobic infections.
If you’re considering using cefiderocol, tell me:
- What organism and infection type you’re dealing with (e.g., cUTI, HABP/VABP)?
- Your patient’s renal function (creatinine clearance) and any other meds?
- Whether you’re looking for a quick dosing example, safety concerns, or how it compares to alternatives?
I can tailor dosing, monitoring plan, and safety notes to your specific scenario.